Dashboard
1
With a growth in Net Profit of 121.14%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 15 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 3,036.37 MM
- ROCE(HY) Highest at 43.38%
- NET PROFIT(Q) At CNY 167.93 MM has Grown at 127.03%
2
With ROE of 33.75%, it has a fair valuation with a 4.31 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 43,727 Million (Large Cap)
13.00
NA
0.47%
-0.17
33.75%
5.07
Revenue and Profits:
Net Sales:
434 Million
(Quarterly Results - Jun 2026)
Net Profit:
192 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.02%
0%
1.02%
6 Months
-13.76%
0%
-13.76%
1 Year
16.32%
0%
16.32%
2 Years
231.28%
0%
231.28%
3 Years
177.28%
0%
177.28%
4 Years
367.44%
0%
367.44%
5 Years
205.78%
0%
205.78%
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
41.68%
EBIT Growth (5y)
74.60%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.28
Tax Ratio
13.10%
Dividend Payout Ratio
7.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.45%
ROE (avg)
3.89%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
4.31
EV to EBIT
11.13
EV to EBITDA
10.82
EV to Capital Employed
4.99
EV to Sales
8.26
PEG Ratio
0.04
Dividend Yield
0.55%
ROCE (Latest)
44.87%
ROE (Latest)
33.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
434.50
330.90
31.31%
Operating Profit (PBDIT) excl Other Income
176.50
63.80
176.65%
Interest
0.00
0.30
-100.00%
Exceptional Items
26.00
13.40
94.03%
Consolidate Net Profit
191.50
85.60
123.71%
Operating Profit Margin (Excl OI)
324.40%
99.10%
22.53%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 31.31% vs 1.10% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 123.71% vs 140.45% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,195.90
1,190.20
252.54%
Operating Profit (PBDIT) excl Other Income
3,244.40
334.50
869.93%
Interest
0.70
1.40
-50.00%
Exceptional Items
50.50
28.90
74.74%
Consolidate Net Profit
2,891.90
691.40
318.27%
Operating Profit Margin (Excl OI)
743.70%
173.60%
57.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 252.54% vs 17.75% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 318.27% vs 143.97% in Dec 2024
About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






